Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
A scientist’s personal journey through breast cancer underscores the urgency for greater empathy in research and healthcare, a patient-centred approach to data dissemination, and more comprehensive, streamlined support for early-career researchers navigating health crises.
With several drugs in use that inhibit the hepatitis B virus polymerases (nucleos(t)ide analogues (or NUCs)), some argue that new direct-acting antiviral drugs, and new NUCs in particular, are not necessary. Here, we make the counter-argument that additional direct-acting antiviral drugs that can potently suppress hepatitis B virus replication, ideally via distinct mechanisms, are still needed and can provide additional therapeutic benefits.
A study in Nature Medicine developed a new clinical test based on a gut metagenome-derived multispecies biomarker panel for the diagnosis of inflammatory bowel disease, which outperformed faecal calprotectin. Shortly after, a study in Cell identified a health-relevant network-based core microbiome that could substantially advance precision microbiome medicine.
Non-communicable diseases represent the primary cause of mortality and morbidity globally, accounting for 74% of all deaths and more than three-quarters of years lived with disability. Here, we argue that metabolic dysfunction-associated steatotic liver disease should be considered a non-communicable disease.
The management of inflammatory bowel disease (IBD) continues to evolve. This Review is a practical guide on the therapeutic toolkit for IBD, with a focus on current and emerging IBD medications, how they relate to management strategies beyond drugs and the importance of the clinician–patient relationship.
In this Review, Ludvigsson and colleagues describe the epidemiological associations between coeliac disease and a variety of complications and comorbidities, and discuss the pathophysiology underlying these complications as well as implications for follow-up and treatment.
In patients with disorders of gut–brain interaction (DGBI), overlapping non-gastrointestinal conditions and symptoms are common, as is overlap among DGBI in different regions of the gastrointestinal tract. This Review describes these overlapping conditions and symptoms, detailing key features, pathophysiology and insights into management.
This Review describes the progression of advanced chronic liver disease (ACLD) from its early stages (compensated ACLD) to more advanced disease (decompensated ACLD). Evidence supporting strategies to manage ACLD and prevent decompensation, as well as the tests used to stratify risk, are discussed.
